explore -WSS

explore

author：entertainment 2025-09-28 00:48:44 - browse：3

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： CDC says it’s too soon to assess risk posed by Covid subvariant

Wikipedia

WSS

FDA greenlights medical device to combat bladder issues

Roche's accidental data boosts hopes for anti

Google says AlphaFold 3 can map a vast universe of biomolecules

Dairy farmers resist CDC push for PPE against bird flu virus

How to improve immunocompromised access to mAb treatments

FDA greenlights medical device to combat bladder issues

leisure time

explore

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sanofi strikes deal with Novavax, boosting the vaccine maker

Walensky prepares to leave CDC — and Congress — behind

Vivek Ramaswamy made waves in the debate, much as in biotech

United colonoscopy coverage change 'may cost lives,' doctors say

Sanofi strikes deal with Novavax, boosting the vaccine maker

In age of alternative facts, a scholarly course on calling out crap

Shionogi licenses Pompe disease therapy from Maze Therapeutics

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

First recipient of genetically engineered pig kidney has died

hotspot

Listen: Vivek Ramaswamy's star turn & leaky drug data

How the drug

Elevance, private equity launch primary care company

After gene therapy, two congenitally deaf children hear for the first time

Steward Health Care files for bankruptcy

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

hotspot

Wikipedia

knowledge

knowledge